Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 5/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.34 |
| ▸ | CTSA | P10619 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27241457 | 1.00 | HTR5A (0.39) | HTR5ARPS6KA2SCN9ALRRK2MAP4K1 | |
| SCHEMBL29945193 | 0.82 | HTR5A (0.39) | HTR5ARPS6KA2SCN9ALRRK2MAP4K1 | |
| SCHEMBL29263384 | 0.79 | SCN9A (0.39) | HTR5ASCN9ACTSA | |
| SCHEMBL29925056 | 0.78 | HTR5A (0.37) | HTR5ARPS6KA2SCN9ALRRK2MAP4K1 | |
| SCHEMBL29876096 | 0.78 | HSP90AA1 (0.42) | HTR5ARPS6KA2SCN9ALRRK2MAP4K1 | |
| SCHEMBL27241451 | 0.78 | HTR5A (0.37) | HTR5ARPS6KA2SCN9ALRRK2MAP4K1 | |
| SCHEMBL28585267 | 0.75 | ALDH1A1 (0.38) | HTR5ARPS6KA2SCN9ALRRK2MAP4K1 | |
| SCHEMBL30662761 | 0.75 | ALDH1A1 (0.38) | HTR5ARPS6KA2SCN9ALRRK2MAP4K1 | |
| SCHEMBL18135229 | 0.72 | RPS6KA2 (0.42) | RPS6KA2LRRK2MAP4K1CHEK1WEE1 | |
| SCHEMBL18128526 | 0.72 | NQO2 (0.36) | HTR5ARPS6KA2MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190871-A1 | KRASG12D INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | YA THERAPEUTICS INC (CN) | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190871-A1 | KRASG12D INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, HRAS | HTR5A 4824/4885RPS6KA2 1935/4885SCN9A 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.